vs

Side-by-side financial comparison of ASGN Inc (ASGN) and Edwards Lifesciences (EW). Click either name above to swap in a different company.

Edwards Lifesciences is the larger business by last-quarter revenue ($1.6B vs $970.0M, roughly 1.7× ASGN Inc). Edwards Lifesciences runs the higher net margin — 23.1% vs 0.6%, a 22.5% gap on every dollar of revenue. On growth, Edwards Lifesciences posted the faster year-over-year revenue change (16.7% vs -3.0%). Over the past eight quarters, Edwards Lifesciences's revenue compounded faster (9.7% CAGR vs -3.2%).

ASGN Inc is a leading U.S.-headquartered professional services and workforce solutions provider. It specializes in supplying skilled talent and consulting services across high-growth segments including information technology, creative, digital, life sciences, and engineering, primarily serving enterprise clients across North America.

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.

ASGN vs EW — Head-to-Head

Bigger by revenue
EW
EW
1.7× larger
EW
$1.6B
$970.0M
ASGN
Growing faster (revenue YoY)
EW
EW
+19.7% gap
EW
16.7%
-3.0%
ASGN
Higher net margin
EW
EW
22.5% more per $
EW
23.1%
0.6%
ASGN
Faster 2-yr revenue CAGR
EW
EW
Annualised
EW
9.7%
-3.2%
ASGN

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
ASGN
ASGN
EW
EW
Revenue
$970.0M
$1.6B
Net Profit
$5.5M
$380.7M
Gross Margin
27.5%
78.0%
Operating Margin
2.9%
1.8%
Net Margin
0.6%
23.1%
Revenue YoY
-3.0%
16.7%
Net Profit YoY
-73.7%
6.8%
EPS (diluted)
$0.13
$0.66

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASGN
ASGN
EW
EW
Q1 26
$970.0M
$1.6B
Q4 25
$980.1M
$1.6B
Q3 25
$1.0B
$1.6B
Q2 25
$1.0B
$1.5B
Q1 25
$968.3M
$1.4B
Q4 24
$985.0M
$1.4B
Q3 24
$1.0B
$1.4B
Q2 24
$1.0B
$1.4B
Net Profit
ASGN
ASGN
EW
EW
Q1 26
$5.5M
$380.7M
Q4 25
$25.2M
$91.2M
Q3 25
$38.1M
$291.1M
Q2 25
$29.3M
$333.2M
Q1 25
$20.9M
$358.0M
Q4 24
$42.4M
$385.6M
Q3 24
$47.5M
$3.1B
Q2 24
$47.2M
$366.3M
Gross Margin
ASGN
ASGN
EW
EW
Q1 26
27.5%
78.0%
Q4 25
28.9%
78.1%
Q3 25
29.4%
77.8%
Q2 25
28.7%
77.5%
Q1 25
28.4%
78.7%
Q4 24
29.0%
78.9%
Q3 24
29.1%
80.6%
Q2 24
29.1%
79.9%
Operating Margin
ASGN
ASGN
EW
EW
Q1 26
2.9%
1.8%
Q4 25
5.7%
9.6%
Q3 25
6.7%
19.8%
Q2 25
5.8%
26.8%
Q1 25
4.8%
27.9%
Q4 24
7.5%
22.6%
Q3 24
7.7%
25.9%
Q2 24
7.8%
26.8%
Net Margin
ASGN
ASGN
EW
EW
Q1 26
0.6%
23.1%
Q4 25
2.6%
5.8%
Q3 25
3.8%
18.7%
Q2 25
2.9%
21.7%
Q1 25
2.2%
25.3%
Q4 24
4.3%
27.8%
Q3 24
4.6%
226.7%
Q2 24
4.6%
26.7%
EPS (diluted)
ASGN
ASGN
EW
EW
Q1 26
$0.13
$0.66
Q4 25
$0.58
$0.16
Q3 25
$0.87
$0.50
Q2 25
$0.67
$0.56
Q1 25
$0.48
$0.61
Q4 24
$0.94
$0.65
Q3 24
$1.06
$5.13
Q2 24
$1.02
$0.61

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASGN
ASGN
EW
EW
Cash + ST InvestmentsLiquidity on hand
$143.6M
Total DebtLower is stronger
$1.5B
Stockholders' EquityBook value
$1.8B
Total Assets
$4.0B
Debt / EquityLower = less leverage
0.82×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASGN
ASGN
EW
EW
Q1 26
$143.6M
Q4 25
$161.2M
$4.2B
Q3 25
$3.8B
Q2 25
$4.1B
Q1 25
$3.9B
Q4 24
$205.2M
$4.0B
Q3 24
$4.4B
Q2 24
$2.0B
Total Debt
ASGN
ASGN
EW
EW
Q1 26
$1.5B
Q4 25
$1.2B
Q3 25
$1.2B
Q2 25
$1.2B
Q1 25
$1.3B
Q4 24
$1.0B
Q3 24
$1.0B
Q2 24
$1.0B
Stockholders' Equity
ASGN
ASGN
EW
EW
Q1 26
$1.8B
Q4 25
$1.8B
$10.3B
Q3 25
$1.8B
$10.2B
Q2 25
$1.8B
$10.5B
Q1 25
$1.8B
$10.1B
Q4 24
$1.8B
$10.0B
Q3 24
$1.8B
$9.5B
Q2 24
$1.8B
$7.4B
Total Assets
ASGN
ASGN
EW
EW
Q1 26
$4.0B
Q4 25
$3.7B
$13.7B
Q3 25
$3.7B
$13.3B
Q2 25
$3.7B
$13.5B
Q1 25
$3.7B
$13.0B
Q4 24
$3.4B
$13.1B
Q3 24
$3.4B
$13.0B
Q2 24
$3.5B
$10.1B
Debt / Equity
ASGN
ASGN
EW
EW
Q1 26
0.82×
Q4 25
0.65×
Q3 25
0.64×
Q2 25
0.66×
Q1 25
0.72×
Q4 24
0.58×
Q3 24
0.58×
Q2 24
0.57×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASGN
ASGN
EW
EW
Operating Cash FlowLast quarter
Free Cash FlowOCF − Capex
$9.1M
FCF MarginFCF / Revenue
0.9%
Capex IntensityCapex / Revenue
1.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$290.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASGN
ASGN
EW
EW
Q1 26
Q4 25
$102.3M
$450.9M
Q3 25
$83.9M
$573.7M
Q2 25
$124.9M
$290.2M
Q1 25
$16.8M
$280.4M
Q4 24
$100.2M
$-127.5M
Q3 24
$135.8M
$351.8M
Q2 24
$90.7M
$371.5M
Free Cash Flow
ASGN
ASGN
EW
EW
Q1 26
$9.1M
Q4 25
$93.7M
$353.5M
Q3 25
$72.0M
$516.2M
Q2 25
$115.8M
$240.9M
Q1 25
$6.6M
$224.4M
Q4 24
$88.9M
$-177.3M
Q3 24
$127.9M
$299.9M
Q2 24
$85.4M
$286.1M
FCF Margin
ASGN
ASGN
EW
EW
Q1 26
0.9%
Q4 25
9.6%
22.5%
Q3 25
7.1%
33.2%
Q2 25
11.3%
15.7%
Q1 25
0.7%
15.9%
Q4 24
9.0%
-12.8%
Q3 24
12.4%
22.1%
Q2 24
8.3%
20.9%
Capex Intensity
ASGN
ASGN
EW
EW
Q1 26
1.0%
Q4 25
0.9%
6.2%
Q3 25
1.2%
3.7%
Q2 25
0.9%
3.2%
Q1 25
1.1%
4.0%
Q4 24
1.1%
3.6%
Q3 24
0.8%
3.8%
Q2 24
0.5%
6.2%
Cash Conversion
ASGN
ASGN
EW
EW
Q1 26
Q4 25
4.06×
4.94×
Q3 25
2.20×
1.97×
Q2 25
4.26×
0.87×
Q1 25
0.80×
0.78×
Q4 24
2.36×
-0.33×
Q3 24
2.86×
0.11×
Q2 24
1.92×
1.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons